Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 30;12(10):1329.
doi: 10.3390/brainsci12101329.

Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection

Affiliations
Review

Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection

Siqi Wang et al. Brain Sci. .

Abstract

Excitatory glutamatergic neurotransmission mediated through N-methyl-D-Aspartate (NMDA) receptors (NMDARs) is essential for synaptic plasticity and neuronal survival. While under pathological states, abnormal NMDAR activation is involved in the occurrence and development of psychiatric disorders, which suggests a directional modulation of NMDAR activity that contributes to the remission and treatment of psychiatric disorders. This review thus focuses on the involvement of NMDARs in the pathophysiological processes of psychiatric mood disorders and analyzes the neuroprotective mechanisms of NMDARs. Firstly, we introduce NMDAR-mediated neural signaling pathways in brain function and mood regulation as well as the pathophysiological mechanisms of NMDARs in emotion-related mental disorders such as anxiety and depression. Then, we provide an in-depth summary of current NMDAR modulators that have the potential to be developed into clinical drugs and their pharmacological research achievements in the treatment of anxiety and depression. Based on these findings, drug-targeting for NMDARs might open up novel territory for the development of therapeutic agents for refractory anxiety and depression.

Keywords: NMDAR; anxiety; depression; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
NMDAR-mediated signaling in brain functioning.

Similar articles

Cited by

References

    1. Fullana M.A., Hidalgo-Mazzei D., Vieta E., Radua J. Coping behaviors associated with decreased anxiety and depressive symptoms during the COVID-19 pandemic and lockdown. J. Affect. Disord. 2020;275:80–81. doi: 10.1016/j.jad.2020.06.027. - DOI - PMC - PubMed
    1. Hyland P., Shevlin M., McBride O., Murphy J., Karatzias T., Bentall R.P., Martinez A., Vallières F. Anxiety and depression in the Republic of Ireland during the COVID-19 pandemic. Acta Psychiatr. Scand. 2020;142:249–256. doi: 10.1111/acps.13219. - DOI - PubMed
    1. Lei L., Huang X., Zhang S., Yang J., Yang L., Xu M. Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus People Unaffected by Quarantine During the COVID-19 Epidemic in Southwestern China. Med. Sci. Monit. 2020;26:e924609. doi: 10.12659/MSM.924609. - DOI - PMC - PubMed
    1. Yuan S., Liao Z., Huang H., Jiang B., Zhang X., Wang Y., Zhao M. Comparison of the Indicators of Psychological Stress in the Population of Hubei Province and Non-Endemic Provinces in China During Two Weeks During the Coronavirus Disease 2019 (COVID-19) Outbreak in February 2020. Med. Sci. Monit. 2020;26:e923767. doi: 10.12659/MSM.923767. - DOI - PMC - PubMed
    1. Salari N., Hosseinian-Far A., Jalali R., Vaisi-Raygani A., Rasoulpoor S., Mohammadi M., Rasoulpoor S., Khaledi-Paveh B. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. Glob. Health. 2020;16:57. doi: 10.1186/s12992-020-00589-w. - DOI - PMC - PubMed

LinkOut - more resources